Intensity Therapeutics, Inc. announced on April 25, 2025, the pricing of a public offering, expecting to raise approximately $2.35 million in gross proceeds. The offering includes the sale of 3,133,333 shares of common stock and accompanying Series B-1 and B-2 common warrants at a combined purchase price of $0.75 per share and warrants. The Series B-1 and B-2 warrants have an exercise price of $0.85 per share.
The closing of the offering is anticipated on or about April 28, 2025, subject to customary closing conditions. The net proceeds from this offering are designated for the enrollment of patients in the INVINCIBLE-4 Study, the treatment of existing patients in the INVINCIBLE-3 Study, and for general working capital purposes. A.G.P./Alliance Global Partners is acting as lead placement agent.
This capital raise is a necessary step for the clinical-stage biotechnology company to secure funding for its ongoing clinical programs, particularly after the recent pause in new enrollment for the Phase 3 INVINCIBLE-3 study. The funds will help support the continued development of INT230-6, its lead drug candidate.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.